Iris Energy Announces Monthly Investor Update for July 2023

Record data center operations at 111°F (44°C)

Appointment of Sunita Parasuraman to Board of Directors

SYDNEY, Australia, Aug. 03, 2023 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: IREN) (“Iris Energy” or “the Company”), a leading owner and operator of institutional-grade, highly efficient proprietary Bitcoin mining data centers powered by 100% renewable energy, today published a monthly investor update for July 2023, containing its results from operations as well as business updates.

Key Highlights

1

Key metrics

2
Jul-23
Average operating hashrate (PH/s) 5,562
Bitcoin mined 423
Mining revenue (US$’000) 12,660
Electricity costs (US$’000) 6,552
Revenue per Bitcoin (US$) 29,939
Electricity costs per Bitcoin (US$) 15,494
  • Corporate:
    • Record data center operations at 111°F (44°C) intake temperatures
      • Maintained stable hashrate through extreme temperatures
      • Demonstrates Iris Energy’s industry-leading data centers
      • Further validates proprietary air-cooled data center design
    • Appointment of Sunita Parasuraman to Board of Directors
      • Senior technology executive, previous experience with Meta (Facebook), VMware, Genentech, and Apple
  • Operations (for the month of July 2023):
    • Average operating hashrate of 5,562 PH/s (flat vs. June)
    • Monthly operating revenue of US$12.7 million (+9% vs. June)
    • 423 Bitcoin mined (-1% vs. June)
    • ~US$0.2 million of estimated power sales at Childress via automated algorithm (~6 Bitcoin equivalent)3
    • Higher electricity costs per Bitcoin ($15.5k vs. $13.0k in June) primarily attributable to higher prices at Childress during the month (typically higher during summer months) and reduced market volatility (lower energy trading proceeds). The Company retains flexibility to reduce future power costs through adjusting miner output in response to changes in mining economics
  • Construction:
    • Childress (Phase 1: 100MW – Texas, USA)
      • 20MW data center operating
      • Civil works for remaining 80MW scheduled to commence in August

Corporate update

Appointment of Sunita Parasuraman to Board of Directors

On July 18, 2023, the Company announced the appointment of Sunita Parasuraman to its Board of Directors. Ms. Parasuraman will also serve as Chair of the Audit and Risk Committee. During her career as a senior technology executive, Ms. Parasuraman has built and scaled world-class teams at Meta (Facebook), VMware, Genentech, and Apple.

Ms. Parasuraman currently serves on the Board of Baldwin Risk Partners (NASDAQ: BRP), a leading publicly-traded insurance distribution company, where she is a member of its Audit and Cyber Risk Committees.

The full announcement can be accessed via the following link.

Livewire Markets, David Bartholomew on ‘The Pitch’

David Bartholomew (Independent Chair) participated in a two-part video series with Livewire Markets to discuss the Company’s infrastructure business model, alternate use cases for its data centers (e.g. HPC and AI), the economics of Bitcoin mining and the attributes that set Iris Energy apart.

The video series can be accessed via the followings links: Video 1 and Video 2.

Canaccord Genuity 43rd Annual Growth Conference

Bom Shin (Head of Capital Markets) is scheduled to participate in a fireside chat with Joseph Vafi (Managing Director, Equity Research) on Wednesday, August 9 at 4.00pm Eastern Time.

The fireside chat will be recorded, and the replay accessible shortly after the event via the following link.

Mr. Shin will also be available for 1×1 meetings with investors. For more information about the conference or to request a 1×1 meeting, please contact a Canaccord Genuity representative.

Canal Flats update (0.8 EH/s, 30MW capacity) – BC, Canada

Canal Flats has been powered by 100% renewable energy since inception4.

The project achieved average monthly operating hashrate of 825 PH/s in July compared to 831 PH/s last month.

Mackenzie update (2.6 EH/s, 80MW capacity) – BC, Canada

Mackenzie has been powered by 100% renewable energy since inception4.

The project achieved average monthly operating hashrate of 2,583 PH/s in July compared to 2,572 PH/s last month.

Prince George update (1.6 EH/s, 50MW capacity) – BC, Canada

Prince George has been powered by 100% renewable energy since inception4.

The project achieved average monthly operating hashrate of 1,592 PH/s in July compared to 1,608 PH/s last month. During the month, the team conducted scheduled maintenance at Prince George (reliability testing of the 25kV cables between the substation and switchgear occurred on July 12-13).

Childress update (0.6 EH/s, 20MW operating / 80MW under construction) – Texas, USA

Childress has been powered by 100% renewable energy since inception via the purchase of RECs.

The project achieved average monthly operating hashrate of 562 PH/s in July compared to 577 PH/s last month.

The data center at Childress successfully maintained stable hashrate at intake temperatures of up to ~111°F (~44°C) (see chart below), further validating the Company’s industry-leading proprietary air-cooled data center design.

The Company’s ability to operate in Texas through extreme temperatures demonstrates the quality of our proprietary data centers, allowing us to enhance the operating environment of our hardware (and thereby extend asset life). This also provides true optionality to transition between mining Bitcoin and energy trading to optimize profitability, in contrast to operators who may be forced to curtail at high temperatures regardless of energy market conditions (i.e. due to operational limitations).

Childress: Hashrate vs. Intake Temperature chart is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/80970e50-c5a4-4c2a-8c06-6df2fdc40e3e

Construction of the remaining 80MW is underway for Phase 1 (first 100MW), with civil works scheduled to commence in August.

The Company’s significant upfront investment in key infrastructure also provides a rapid, efficient and near-term growth pathway for the subsequent 500MW of 600MW power capacity at the site.

Community engagement

Canal Flats is pleased to advise it has renewed its sponsorship of the Columbia Valley Rockies Hockey team for the 2023/2024 season. A sponsorship of C$10,000 will go towards supporting the local youth for what is looking to be another exciting hockey season.

Applications have now closed for the 2023 Community Grants Programs for Mackenzie and Prince George. The Company is currently reviewing submissions and successful recipients are expected to be announced in the coming months.

Applications are currently being accepted for the 2023 Community Grants Program for Childress, with Iris Energy to invest up to US$100,000 into local non-profit organizations in the community.

Future development sites

Development works continued across additional sites in Canada, the USA and Asia-Pacific, which have the potential to support up to an additional >1GW of aggregate capacity that can power growth beyond the Company’s 760MW of announced capacity.

Operating and financial results

Daily average operating hashrate chart is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bb12d311-6313-4d48-9ad8-a6e153a7c689

Technical commentary

The Company’s average operating hashrate was 5,562 PH/s in July (compared to 5,587 PH/s in June) with the marginal decrease primarily attributable to scheduled maintenance at Prince George (reliability testing of the 25kV cables between the substation and switchgear occurred on July 12-13). The decrease in Bitcoin mined (423 vs. 428 in June) was primarily attributable to a decrease in network transaction fees and an increase in network difficulty. The increase in electricity costs per Bitcoin ($15.5k vs. $13.0k in June) was primarily attributable to higher prices at Childress (typically higher during summer months) and reduced market volatility (lower energy trading proceeds), noting the Company retains flexibility to reduce future power costs through adjusting miner output in response to changes in mining economics.

Operating May-23 Jun-23 Jul-23
Renewable energy usage (MW)

5
167 169 170
Avg operating hashrate (PH/s) 5,510 5,587 5,562

Financial (unaudited)

2
May-23 Jun-23 Jul-23
Bitcoin mined 508 428 423
Mining revenue (US$’000) 13,526 11,653 12,660
Electricity costs (US$’000) 6,056 5,572 6,552
Revenue per Bitcoin (US$) 26,628 27,211 29,939
Electricity costs per Bitcoin (US$) 11,922 13,011 15,494

Site Capacity

(MW)
Capacity
(EH/s)


6
Timing Status
Canal Flats (BC, Canada) 30 0.8 Complete Operating
Mackenzie (BC, Canada) 80 2.6 Complete Operating
Prince George (BC, Canada) 50 1.6 Complete Operating
Total (BC, Canada) 160 5.0    
Childress (Texas, USA) 20 0.6 Complete Operating
Total Operating (Canada & USA) 180 5.6    
Childress (Texas, USA) 80 3.57 Early 20248 Under construction
Total (Canada & USA) 260 9.1    



About Iris Energy

Iris Energy is a sustainable Bitcoin mining company that supports the decarbonization of energy markets and the global Bitcoin network.

  • 100% renewables: Iris Energy targets markets with low-cost, under-utilized renewable energy, and where the Company can support local communities
  • Long-term security over infrastructure, land and power supply: Iris Energy builds, owns and operates its electrical infrastructure and proprietary data centers, providing long-term security and operational control over its assets
  • Seasoned management team: Iris Energy’s team has an impressive track record of success across energy, infrastructure, renewables, finance, digital assets and data centers with cumulative experience in delivering >$25bn in energy and infrastructure projects globally

Forward-Looking Statements

This investor update includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Iris Energy’s future financial or operating performance. For example, forward-looking statements include but are not limited to the Company’s business strategy, expected operational and financial results, and expected increase in power capacity and hashrate. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “may,” “can,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “target”, “will,” “estimate,” “predict,” “potential,” “continue,” “scheduled” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

These forward-looking statements are based on management’s current expectations and beliefs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Iris Energy’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: Iris Energy’s limited operating history with operating losses; electricity outage, limitation or availability of electricity supply or increase in electricity costs, as well as limitations on the availability of electrical supply for Bitcoin mining due to restrictions imposed by governmental authorities or otherwise; long term outage or limitation of the internet connection at Iris Energy’s sites; any critical failure of key electrical or data center equipment; serial defects or underperformance with respect to Iris Energy’s equipment; failure of suppliers to perform under the relevant supply contracts for equipment that has already been procured which may delay Iris Energy’s expansion plans; supply chain and logistics issues for Iris Energy or Iris Energy’s suppliers; cancellation or withdrawal of required operating and other permits and licenses; customary risks in developing greenfield infrastructure projects; Iris Energy’s evolving business model and strategy; Iris Energy’s ability to successfully manage its growth; Iris Energy’s ability to raise additional financing (whether because of the conditions of the markets, Iris Energy’s financial condition or otherwise) on a timely basis, or at all, which could adversely impact the Company’s ability to meet its capital commitments (including payments due under any hardware purchase contracts or debt financing obligations) and the Company’s growth plans; the failure of Iris Energy’s wholly-owned special purpose vehicles to make required payments of principal and/or interest under their limited recourse equipment financing arrangements when due or otherwise comply with the terms thereof, as a result of which the lender thereunder has declared the entire principal amount of each loan to be immediately due and payable, and is taking steps to enforce the indebtedness and its rights in the Bitcoin miners with respect to certain of such loans and other assets securing such loans, including appointing a receiver with respect to such special purpose vehicles, which is expected to result in the loss of the relevant Bitcoin miners securing such loans and has materially reduced the Company’s operating capacity, and could also lead to bankruptcy or liquidation of the relevant special purpose vehicles, and materially and adversely impact the Company’s business, operating expansion plans, financial condition, cash flows and results of operations; the terms of any additional financing or any refinancing, restructuring or modification to the terms of any existing financing, which could be less favorable or require Iris Energy to comply with more onerous covenants or restrictions, any of which could restrict its business operations and adversely impact its financial condition, cash flows and results of operations; competition; Bitcoin prices, global hashrate and the market value of Bitcoin miners, any of which could adversely impact its financial condition, cash flows and results of operations, as well as its ability to raise additional financing and the ability of its wholly owned special purpose vehicles to make required payments of principal and/or interest on their equipment financing facilities; risks related to health pandemics including those of COVID-19; changes in regulation of digital assets; and other important factors discussed under the caption “Risk Factors” in Iris Energy’s annual report on Form 20-F filed with the SEC on September 13, 2022, and the Company’s report on Form 6-K filed with the SEC on February 15, 2023, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations section of Iris Energy’s website at https://investors.irisenergy.co.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this investor update. Any forward-looking statement that Iris Energy makes in this investor update speaks only as of the date of such statement. Except as required by law, Iris Energy disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Preliminary Financial Information

The preliminary financial information for the month of July 2023 included in this investor update is not subject to the same closing procedures as our unaudited quarterly financial results and has not been reviewed by our independent registered public accounting firm. The preliminary financial information included in this investor update does not represent a comprehensive statement of our financial results or financial position and should not be viewed as a substitute for unaudited financial statements prepared in accordance with International Financial Reporting Standards. Accordingly, you should not place undue reliance on the preliminary financial information included in this investor update.

Contacts

Media

Jon Snowball
Domestique
+61 477 946 068

Investors

Lincoln Tan
Iris Energy
+61 407 423 395
[email protected]

To keep updated on Iris Energy’s news releases and SEC filings, please subscribe to email alerts at https://investors.irisenergy.co/ir-resources/email-alerts.

_________________________________________________

1 All timing references in this investor update are to calendar months, in each case unless otherwise specified.
2 Bitcoin and Bitcoin mined in this investor update are presented in accordance with our revenue recognition policy which is determined on a Bitcoin received basis (post deduction of mining pool fees as applicable).
3 Represents unaudited estimated power credits (primarily driven by curtailment) under hedge contracts (based on current meter data and average quarter hour spot prices) and are reflected within the electricity costs. Bitcoin equivalent calculated by dividing the estimated power credits by the average revenue per Bitcoin of $29,939 for the month of July. Current internal estimate as monthly electricity invoices have not yet been issued for Childress.
4 Currently approximately 97% directly from renewable energy sources; approximately 3% from purchase of RECs.
5 Comprises actual power usage for Canal Flats, Mackenzie, Prince George and Childress. Canal Flats, Mackenzie and Prince George have been powered by 100% renewable energy since inception of which approximately 97% is directly from renewable energy sources; approximately 3% is from the purchase of RECs. Childress has been powered by 100% renewable energy since inception via the purchase of RECs.
6 Reflects estimated hashrate capacity by site assuming full utilization of existing available data center capacity with Bitmain S19j Pro miners.
7 Assumes purchase of Bitmain S19 XP miners. Additional miners have not yet been purchased and the Company will continue to monitor the market for purchase opportunities. Hashrate figures may change depending on miner procurement selection.
8 Indicative timing for completion of data centers.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0347c5ac-9ca8-482a-83df-a2556298e7f9

https://www.globenewswire.com/NewsRoom/AttachmentNg/ce69c5d1-caa1-48f7-9460-f7c32abda1ca



ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound

Garden City, NY, Aug. 03, 2023 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), as a potential safer, more efficacious oncology therapy wholly unlike standard chemotherapeutic agents.

“ProPhase Labs continues to act as a disruptor in the therapeutic development space by employing only the most advanced, cutting-edge technology in the pursuit of clinical benefit and program success,” commented developmental lead Dr. Matt Halpert Ph.D. “Long gone are the days of blind experimentation with the hopes of achieving promising results.. We have entered an era in which if you are not at the forefront of high throughput analysis and technology for therapeutical development, you are not in therapeutical development.” With that mindset, ProPhase Labs has joined forces with Certis Oncology to use one-of-a-kind, robust, machine learning technology to exponentially improve the chances of successful development in the oncological therapeutic space.

“We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs. “By further mining all existing data sets, we are able to cross-reference genetic signatures, signaling pathways, and Linebacker responsiveness with Artificial Intelligence (AI), which we believe will greatly assist us in honing in on the most likely cancers and pathways that may be inhibited by Linebacker in the big picture.”

“Using Certis’s proprietary technology, CertisAI Predictive Oncology Intelligence, we determined that Linebacker may be effective against several types of cancer, but importantly not all cancers,” Dr. Halpert continued. “Selectivity is good, and being able to determine now what is most likely to be clinically relevant only improves the overall odds of success.” ProPhase intends to continue to line up AI-generated information with sound medical and scientific insights from experienced players to further guide development towards a regulatory pathway with lower barriers to entry and severe need in the clinic.

“Our team is very pleased to be working with ProPhase on the Linebacker initiative. By leveraging the predictive power of artificial intelligence and machine learning, then validating in silico predictions using advanced, more clinically relevant biological models of cancer, the scientific community will answer complex questions about how to treat each unique cancer—faster,” said Peter Ellman, President and CEO of Certis.

“Of course, this is more work on the front end, but it would be short-sighted and disingenuous to forego these opportunities to protect against a future, exponentially larger, burn,” added Karkus. “Savvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward. We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies. This is a nominal amount given our greater than $40 million in net working capital. With positive results and subject to the necessary regulatory approvals, we believe we will be well situated to explore significant licensing opportunities with major pharma.”

With this extensive data set now in hand, ProPhase will proceed to the next level of IND-enabling development for the potentially revolutionary Linebacker drug. Focused and detailed studies are already underway.

About Linebacker

Linebacker is a modified polyphenol. Polyphenols are substances found in many nuts, vegetables and berries. Linebacker compounds are modified Myricetin, which is a common plant-derived flavonoid. Myricetin exhibits a wide range of activities that include strong antioxidant, anti-cancer, antidiabetic and anti-inflammatory activities. It displays activities that are related to the central nervous system.

LB-1 is Mono-chlorinated Myricetin with a Chlorine atom substituted for the Hydroxy group at 5’ (position 5 on the B-ring). LB-2 is Di-chlorinated Myricetin with Chlorine atoms substituted for the Hydroxy groups at 5’ and 7 (position 5 on the B-ring and position 7 on the A-ring).

About
Certis
Oncology Solutions, Inc.

Certis is a precision oncology and translational science company. Its product is “Oncology Intelligence”—highly predictive therapeutic response data derived from advanced models of cancer. We partner with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Using our proprietary artificial intelligence/machine learning platform and more clinically relevant, patient-derived tumor models, we bring certainty to lead candidate selection and help secure clear and compelling evidence of drug efficacy. Established in 2016, Certis operates a CLIA-certified laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.

About ProPhase Labs

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics, therapeutics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.

Forward Looking Statements

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, our beliefs regarding the potential of Linebacker-1 to be a safer, more efficacious oncology therapy, the potential for artificial intelligence to improve the Company’s chances of successful development of Linebacker-1, and the projected timelines for the Company’s preclinical and clinical programs and commercialization. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

For more information, visit www.ProPhaseLabs.com

Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.
267-880-1111
[email protected]

Retail Investor Relations Contact:

Renmark Financial Communications
John Boidman
514-939-3989
[email protected]

Source: ProPhase Labs, Inc.

###



Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update.

To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 8451277. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the Company’s website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived under “Presentations, Events & Webcasts” in the Investors section of the Company’s website at http://ir.darebioscience.com and available for replay until August 24, 2023.

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women’s health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder (FSAD) and/or female sexual interest/arousal disorder (FSIAD) utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth / Julia Weilman
Burns McClellan
[email protected][email protected]
646.930.4406 / 646.732.4443

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Evoke Canale
[email protected]
619.849.5383

Source: Daré Bioscience, Inc.

 



RYVYL Announces Completion of Initial Steps Under the Exchange Agreement Reducing Debt and Increasing Shareholder Equity and Cash Flow

SAN DIEGO, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation capabilities to conduct payment transactions, announced today the Company on July 31, 2023 closed the first of two exchange transactions, with an existing noteholder (the “Noteholder”) under the terms of an Exchange Agreement, dated July 25, 2023 (the “Exchange Agreement”), and issued 6,000 shares of Series A Convertible Preferred Stock to the Noteholder in exchange for $4,297,000 of the outstanding principal balance of the Note and $1,703,000 of accrued interest.

As recently announced in a July 26, 2023 press release, under the terms of the Exchange Agreement, the Company and the Noteholder agreed to exchange, in two separate exchanges, an aggregate of $22.703 million of the outstanding principal and interest under an outstanding convertible note, held by the Noteholder, for 15,000 shares of the Company’s s Series A Preferred Convertible Stock . The remaining $16,703,000 in principal, not closed on, under the terms of the Exchange Agreement, is to be exchanged for 9,000 shares of Series A Convertible Preferred Stock at an additional closing, subject to the Company’s having satisfied certain conditions, including obtaining stockholder approval for the issuance of all shares of common stock underlying the Series A Convertible Preferred Stock, in accordance with the rules and regulations of NASDAQ.

Additional information can be found in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 1, 2023, and available on RYVYL’s Investor Relations website https://investors.ryvyl.com/financials/sec-filings/

About RYVYL

RYVYL Inc. (NASDAQ: RVYL) was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business, and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation capabilities, RYVYL is reinventing the future of financial transactions using its coyni® stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017 in San Diego, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity theft protection, and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants, and consumers around the globe. www.ryvyl.com

Cautionary Note Regarding Forward-Looking Statements.

This press release includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements regarding the timing of the filing of the aforementioned periodic reports. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements, including the risk that the completion and filing of the aforementioned periodic reports will take longer than expected and that additional information may become known prior to the expected filing of the aforementioned periodic reports with the SEC. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

Investor Relations Contact:

Mark Schwalenberg
MZ Group – MZ North America
312-261-6430
[email protected]
www.mzgroup.us



Portillo’s Inc. Announces Second Quarter 2023 Financial Results

OAK BROOK, Ill., Aug. 03, 2023 (GLOBE NEWSWIRE) — Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the second quarter ended June 25, 2023.

Michael Osanloo, President and Chief Executive Officer of Portillo’s, said, “We delivered another quarter of strong results that highlight the durability of our brand. We feel great about our recent new restaurant performance and are also delivering solid results in our core. To sustain this positive trajectory, we continue to focus on quality and execution. Our restaurants are fully-staffed, and we empower our Team Members to prioritize the guest experience by serving delicious, high-quality food in an engaging environment at a great price point. This creates a consistently outstanding experience for both our Team Members and guests.”

Financial Highlights for the Second Quarter 2023 vs. Second Quarter 2022:

  • Total revenue increased 12.3% or $18.6 million to $169.2 million;
  • Same restaurant sales increased 5.9%;
  • Operating income decreased $0.1 million to $17.4 million;
  • Net income decreased $0.9 million to $9.9 million;
  • Restaurant-Level Adjusted EBITDA* increased $4.3 million to $42.7 million; and
  • Adjusted EBITDA* increased $1.6 million to $29.2 million.

*Adjusted EBITDA and Restaurant-Level Adjusted EBITDA are non-GAAP measures. Please see definitions and the reconciliations of these non-GAAP measures in the accompanying financial information below.

Recent Developments and Trends

We continue to see revenue growth due to our new restaurant openings, as well as same-restaurant sales growth. Total revenue grew 12.3% during the quarter ended June 25, 2023 and 14.1% for the two quarters ended June 25, 2023. Same-restaurant sales grew 5.9% during the quarter ended June 25, 2023, compared to 1.9% same-restaurant sales growth during the same quarter in 2022. Same-restaurant sales grew 7.4% during the two quarters ended June 25, 2023, compared to 4.8% same-restaurant sales growth during the two quarters ended June 26, 2022.

During the quarter ended June 25, 2023, we opened one new restaurant in Gilbert, Arizona for a total of 76 restaurants, including a restaurant owned by C&O, of which Portillo’s owns 50% of the equity. Our six new restaurants opened in 2022 and 2023, positively impacted revenues by approximately $10.4 million and $20.9 million in the quarter and two quarters ended June 25, 2023, respectively. We plan to open eight more new restaurants in the third and fourth quarters of 2023.

In the quarter and two quarters ended June 25, 2023, we continued to experience commodity inflation, but to a lesser extent than we saw in 2022. Commodity inflation was 5.5% and 7.1% for the quarter and two quarters ended June 25, 2023, respectively, compared to 15.2% and 15.5% for the quarter and two quarters ended June 26, 2022. We expect our overall commodity inflation to ease over the course of the year and currently estimate commodity inflation in the mid-single digits for the full fiscal year. Labor expenses, as a percentage of revenue, slightly increased during the second quarter of 2023 compared to the same quarter in 2022. For the two quarters ended June 25, 2023, we experienced a decline in labor expenses, as a percentage of revenue, compared to the two quarters ended June 26, 2022 primarily due to increases in our average check, partially offset by additional wage investments. Subsequent to the quarter, we made additional wage investments in our team members. We currently estimate mid-single digit labor inflation for the full fiscal year. During mid-January 2023 and at the beginning of May 2023, we increased certain menu prices to reflect an approximate 2.0% and 3.0% price increase, respectively, to continue to combat inflationary cost pressures and progress towards our goal to improve Restaurant-Level Adjusted EBITDA margins for fiscal 2023. We will continue to monitor the environment and make additional pricing decisions, if necessary.

In the quarter ended June 25, 2023, operating income margin and Restaurant-Level Adjusted EBITDA Margin continued to improve since the fourth quarter of 2022. We believe this improvement was the result of our ongoing efforts to deploy strategic pricing actions, elevate guest experiences, and implement operational efficiencies.

Review of Second Quarter 2023 Financial Results

Revenues for the quarter ended June 25, 2023 were $169.2 million compared to $150.6 million for the quarter ended June 26, 2022, an increase of $18.6 million or 12.3%. The increase in revenues was primarily attributed to the opening of two restaurants in the second through fourth quarters of 2022 and four restaurants during the two quarters ended June 25, 2023 and an increase in our same-restaurant sales. Same-restaurant sales increased 5.9% during the second quarter ended June 25, 2023, which was attributable to an increase in average check of 7.1% and a 1.2% decrease in transactions. The higher average check was driven by an approximate 9.9% increase in certain menu prices partially offset by product mix. New restaurants positively impacted revenues by approximately $10.4 million in the quarter ended June 25, 2023. For the purpose of calculating same-restaurant sales for June 25, 2023, sales for 66 restaurants were included in the Comparable Restaurant Base (as defined in “Selected Operating Data” below).

Total restaurant operating expenses for the second quarter ended June 25, 2023 were $126.5 million compared to $112.2 million for the second quarter ended June 26, 2022, an increase of $14.2 million or 12.7%. The increase in restaurant operating expenses was driven by the opening of two restaurants in the second through fourth quarters of 2022 and four restaurants during the two quarters ended June 25, 2023. Additionally, food, beverage and packaging costs were negatively impacted by a 5.5% increase in commodity prices, partially offset by lower third-party delivery commissions. Labor expense increases were also driven by incremental investments to support our team members, including annual rate increases primarily made in July 2022, and higher variable-based compensation. These labor increases were partially offset by operational efficiencies. Operating expenses increased due to an increase in repair and maintenance expenses, credit card fees, insurance, and utilities.

General and administrative expenses for the quarter ended June 25, 2023 were $19.6 million compared to $15.4 million for the quarter ended June 26, 2022, an increase of $4.2 million or 27.0%. This increase was primarily driven by increases in variable-based compensation, salaries and wages attributable to annual rate increases, the filling of open positions, software and other licensing fees, and advertising expenses.

Operating income for the second quarter ended June 25, 2023 and June 26, 2022 was $17.4 million. There was an immaterial decrease in operating income in the second quarter ended June 25, 2023 compared to the second quarter ended June 26, 2022 due to the aforementioned increase in revenues and lower pre-opening expenses due to the timing and geographic location of activities related to our planned restaurant openings, more than offset by the aforementioned increases in expenses and higher depreciation and amortization.

Net income for the second quarter ended June 25, 2023 was $9.9 million compared to net income of $10.8 million for the second quarter ended June 26, 2022, a decrease of $0.9 million or 8.0%. The decrease in net income was primarily due to a decrease in the Tax Receivable Agreement liability adjustment of $1.2 million, an increase in interest expense of $0.4 million, and the aforementioned decrease in operating income, partially offset by a decrease in income tax expense of $0.8 million. The $0.4 million increase in interest expense was primarily driven by a higher effective interest rate attributable to the year over year rising interest rate environment, partially offset by the improved lending terms associated with our 2023 Term Loan and 2023 Revolver Facility.

Restaurant-Level Adjusted EBITDA* for the second quarter ended June 25, 2023 was $42.7 million compared to $38.4 million for the second quarter ended June 26, 2022, an increase of $4.3 million or 11.3%.

Adjusted EBITDA* for the second quarter ended June 25, 2023 was $29.2 million compared to $27.6 million for the second quarter ended June 26, 2022, an increase of $1.6 million or 5.8%.

*A reconciliation of Restaurant-Level Adjusted EBITDA and Adjusted EBITDA and the nearest GAAP financial measure is included under “Non-GAAP Financial Measures” in the accompanying financial information below.

Development Highlights

During the two quarters ended June 25, 2023, we opened the remaining four restaurants that were planned for 2022. The opening of these restaurants brings the total restaurant count to 76, including a restaurant owned by C&O of which Portillo’s owns 50% of the equity.

Below are the restaurants opened since the beginning of fiscal 2023:

Location Opening Date
Kissimmee, Florida December 2022
The Colony, Texas January 2023
Tucson, Arizona February 2023
Gilbert, Arizona March 2023
   

The following definitions apply to these terms as used in this release:

Same-Restaurant Sales – The change in same-restaurant sales is the percentage change in year-over-year revenue (excluding gift card breakage) for the Comparable Restaurant Base, excluding a restaurant that is owned by C&O. The Comparable Restaurant Base is defined as the number of restaurants open for at least 24 full fiscal periods. As of June 25, 2023 and June 26, 2022, there were 66 and 61 restaurants in our Comparable Restaurant Base, respectively.

A change in same-restaurant sales growth is the result of a change in restaurant transactions, average guest check, or a combination of the two. We gather daily sales data and regularly analyze the guest transaction counts and the mix of menu items sold to strategically evaluate menu pricing and demand. Measuring our same-restaurant sales growth allows management to evaluate the performance of our existing restaurant base. We believe this measure provides a consistent comparison of restaurant sales results and trends across periods within our core, established restaurant base, unaffected by results of restaurant openings and enables investors to better understand and evaluate the Company’s historical and prospective operating performance.

Average Unit Volume (“AUV”) – AUV is the total revenue (excluding gift card breakage) recognized in the Comparable Restaurant Base, including a restaurant that is owned by C&O, divided by the number of restaurants in the Comparable Restaurant Base, including C&O, by period.

This key performance indicator allows management to assess changes in consumer spending patterns at our restaurants and the overall performance of our restaurant base.

Adjusted EBITDA and Adjusted EBITDA Margin – Adjusted EBITDA represents net income (loss) before depreciation and amortization, interest expense and income taxes, adjusted for the impact of certain non-cash and other items that we do not consider in our evaluation of ongoing core operating performance as identified in the reconciliation of net income (loss), the most directly comparable GAAP measure to Adjusted EBITDA. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of total revenues. See also “Non-GAAP Financial Measures.”

Restaurant-Level Adjusted EBITDA and Restaurant-Level Adjusted EBITDA Margin – Restaurant-Level Adjusted EBITDA is defined as revenue, less restaurant operating expenses, which include food, beverage and packaging costs, labor expenses, occupancy expenses and other operating expenses. Restaurant-Level Adjusted EBITDA excludes corporate level expenses and depreciation and amortization on restaurant property and equipment. Restaurant-Level Adjusted EBITDA Margin represents Restaurant-Level Adjusted EBITDA as a percentage of revenue. See also “Non-GAAP Financial Measures.”

For more information about the Company’s Non-GAAP measures, how they are calculated and reconciled and why management believes that they are useful, see “Non-GAAP Financial Measures” below.

Earnings Conference Call and Development Day

The Company will host a conference call to discuss its financial results for the second quarter ended June 25, 2023 on Thursday, August 3, 2023, at 10:00 AM ET. The conference call can be accessed live over the phone by dialing 1-877-407-3982 (toll-free) or 1-201-493-6780 (international). A telephone replay will be available shortly after the call has concluded and can be accessed by dialing 1-412-317-6671; the passcode is 13735738. The webcast will be available at www.portillos.com under the investors section and will be archived on the site shortly after the call has concluded.

We will also be hosting a Development Day on Tuesday, September 19, 2023 in Dallas-Fort Worth. This event will focus on Portillo’s development strategy as a key driver of the Company’s future growth.

About Portillo’s

In 1963, Dick Portillo invested $1,100 into a small trailer to open the first Portillo’s hot dog stand in Villa Park, IL, which he called “The Dog House.” Years later, Portillo’s (NASDAQ: PTLO) has grown to more than 70 restaurants across 10 states. Portillo’s is best known for its Chicago-style hot dogs, Italian beef sandwiches, char-grilled burgers, fresh salads and famous chocolate cake.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). All statements other than statements of historical fact are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business, and are based on currently available operating, financial and competitive information which are subject to various risks and uncertainties, so you should not place undue reliance on forward-looking statements. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “commit,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other similar expressions.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements, so you should not unduly rely on these statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:

  • risks related to or arising from our organizational structure;
  • risks of food-borne illness and food safety and other health concerns about our food;
  • the impact of unionization activities of our restaurant workers on our operations and profitability;
  • the impact of recent bank failures on the marketplace, including the ability to access credit;
  • risks associated with our reliance on certain information technology systems and potential failures or interruptions;
  • privacy and cyber security risks related to our digital ordering and payment platforms for our delivery business;
  • the impact of competition, including from our competitors in the restaurant industry or our own restaurants;
  • the increasingly competitive labor market and our ability to attract and retain the best talent and qualified employees;
  • the impact of federal, state or local government regulations relating to privacy, data protection, advertising and consumer protection, building and zoning requirements, costs or ability to open new restaurants, or sale of food and alcoholic beverage control regulations;
  • inability to achieve our growth strategy, such as the availability of suitable new restaurant sites in existing and new markets and opening of new restaurants at the anticipated rate and on the anticipated timeline;
  • increases in food and other operating costs, tariffs and import taxes, and supply shortages;
  • the potential future impact of COVID-19 (including any variant) on our results of operations, supply chain or liquidity; and
  • other risks identified in our filings with the Securities and Exchange Commission (the “SEC”).

All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this press release in the context of the risks and uncertainties disclosed in the Company’s most recent Annual Report on Form 10-K, filed with the SEC. All of the Company’s SEC filings are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release are made only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Investor Contact:

Barbara Noverini, CFA
[email protected] 

Media Contact:

ICR, Inc.
[email protected] 

PORTILLO’S INC

CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)

(in thousands, except share and per share data)
       
  Quarter Ended   Two Quarters Ended
  June 25, 2023   June 26, 2022   June 25, 2023   June 26, 2022
REVENUES, NET $ 169,182     100.0 %   $ 150,623     100.0 %   $ 325,242     100.0 %   $ 285,105     100.0 %
                               
COST AND EXPENSES:                              
Restaurant operating expenses:                              
Food, beverage and packaging costs   56,229     33.2 %     51,774     34.4 %     109,856     33.8 %     98,040     34.4 %
Labor   43,153     25.5 %     37,906     25.2 %     83,612     25.7 %     75,219     26.4 %
Occupancy   8,237     4.9 %     7,379     4.9 %     16,688     5.1 %     15,134     5.3 %
Other operating expenses   18,832     11.1 %     15,178     10.1 %     37,536     11.5 %     30,343     10.6 %
Total restaurant operating expenses   126,451     74.7 %     112,237     74.5 %     247,692     76.2 %     218,736     76.7 %
                               
General and administrative expenses   19,609     11.6 %     15,439     10.3 %     38,387     11.8 %     31,126     10.9 %
Pre-opening expenses   275     0.2 %     423     0.3 %     2,619     0.8 %     979     0.3 %
Depreciation and amortization   5,941     3.5 %     5,309     3.5 %     11,610     3.6 %     10,514     3.7 %
Net income attributable to equity method investment   (381 )   (0.2) %     (275 )   (0.2) %     (588 )   (0.2) %     (398 )   (0.1) %
Other (income) loss, net   (97 )   (0.1) %     51     %     (354 )   (0.1) %     (105 )   %
OPERATING INCOME   17,384     10.3 %     17,439     11.6 %     25,876     8.0 %     24,253     8.5 %
Interest expense   6,523     3.9 %     6,097     4.0 %     13,966     4.3 %     12,196     4.3 %
Tax Receivable Agreement liability adjustment   (579 )   (0.3) %     (1,754 )   (1.2) %     (1,163 )   (0.4) %     (1,754 )   (0.6) %
Loss on debt extinguishment       %         %     3,465     1.1 %         %
INCOME BEFORE INCOME TAXES   11,440     6.8 %     13,096     8.7 %     9,608     3.0 %     13,811     4.8 %
Income tax expense   1,542     0.9 %     2,340     1.6 %     983     0.3 %     2,505     0.9 %
NET INCOME   9,898     5.9 %     10,756     7.1 %     8,625     2.7 %     11,306     4.0 %
Net income attributable to non-controlling interests   3,110     1.8 %     5,645     3.7 %     2,351     0.7 %     6,001     2.1 %
NET INCOME ATTRIBUTABLE TO PORTILLO’S INC. $ 6,788     4.0 %   $ 5,111     3.4 %   $ 6,274     1.9 %   $ 5,305     1.9 %
                               
Net income per common share attributable to Portillo’s Inc.:                              
Basic $ 0.12         $ 0.14         $ 0.12         $ 0.15      
Diluted $ 0.12         $ 0.13         $ 0.11         $ 0.13      
                               
Weighted-average common shares outstanding:                              
Basic   54,964,649           35,991,079           52,252,053           35,899,125      
Diluted   58,550,057           39,687,090           55,806,455           39,839,292      

PORTILLO’S INC.

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in thousands, except share and per share data)
 
  June 25, 2023   December 25, 2022
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents and restricted cash $ 22,457   $ 44,427  
Accounts receivable   11,496     8,590  
Inventory   6,493     7,387  
Prepaid expenses   5,139     4,922  
Total current assets   45,585     65,326  
Property and equipment, net   250,443     227,036  
Operating lease assets   179,449     166,808  
Goodwill   394,298     394,298  
Trade names   223,925     223,925  
Other intangible assets, net   30,356     31,800  
Equity method investment   16,373     16,274  
Deferred tax assets   186,997     150,497  
Other assets   4,061     4,119  
Total other assets   856,010     820,913  
TOTAL ASSETS $ 1,331,487   $ 1,280,083  
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
CURRENT LIABILITIES:      
Accounts payable $ 24,147   $ 30,273  
Current portion of long-term debt   7,500     4,155  
Current portion of Tax Receivable Agreement liability   6,309     813  
Short-term debt   10,000      
Current deferred revenue   4,696     7,292  
Short-term operating lease liability   5,053     4,849  
Accrued expenses   31,322     29,915  
Total current liabilities   89,027     77,297  
LONG-TERM LIABILITIES:      
Long-term debt, net of current portion   289,168     314,425  
Tax Receivable Agreement liability   295,696     252,003  
Long-term operating lease liability   217,989     200,166  
Other long-term liabilities   3,151     3,291  
Total long-term liabilities   806,004     769,885  
Total liabilities   895,031     847,182  
       
COMMITMENTS AND CONTINGENCIES      
       
STOCKHOLDER’S EQUITY:      
Preferred stock, $0.01 par value per share, 10,000,000 shares authorized, none issued or outstanding        
Class A common stock, $0.01 par value per share, 380,000,000 shares authorized, and 55,073,993 and 48,420,723 shares issued and outstanding at June 25, 2023 and December 25, 2022, respectively.   551     484  
Class B common stock, $0.00001 par value per share, 50,000,000 shares authorized, and 17,472,926 and 23,837,162 shares issued and outstanding at June 25, 2023 and December 25, 2022, respectively.        
Additional paid-in-capital   301,622     260,664  
Retained earnings (accumulated deficit)   1,462     (4,812 )
Total stockholders’ equity attributable to Portillo’s Inc.   303,635     256,336  
Non-controlling interest   132,821     176,565  
Total stockholders’ equity   436,456     432,901  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 1,331,487   $ 1,280,083  

PORTILLO’S INC

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in thousands)
   
  Two Quarters Ended
  June 25, 2023   June 26, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income $ 8,625     $ 11,306  
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization   11,610       10,514  
Amortization of debt issuance costs and discount   620       1,243  
Loss on sales of assets   496       107  
Equity-based compensation   7,720       7,649  
Deferred rent and tenant allowance         2,112  
Deferred income tax expense   983       2,505  
Tax Receivable Agreement liability adjustment   (1,163 )     (1,754 )
Amortization of deferred lease incentives         (166 )
Gift card breakage   (528 )     (474 )
Loss on debt extinguishment   3,465        
Changes in operating assets and liabilities:      
Accounts receivables   (906 )     (1,089 )
Receivables from related parties   (141 )     (66 )
Inventory   894       439  
Other current assets   (218 )     754  
Operating lease assets   3,880        
Accounts payable   (2,779 )     (2,908 )
Accrued expenses and other liabilities   (559 )     (6,140 )
Operating lease liabilities   (1,359 )      
Deferred lease incentives   850       1,251  
Other assets and liabilities   (181 )     76  
NET CASH PROVIDED BY OPERATING ACTIVITIES   31,309       25,359  
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchase of property and equipment   (37,359 )     (13,940 )
Proceeds from the sale of property and equipment   33       30  
NET CASH USED IN INVESTING ACTIVITIES   (37,326 )     (13,910 )
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from short-term debt, net   10,000        
Proceeds from long-term debt   300,000        
Payments of long-term debt   (322,428 )     (1,662 )
Proceeds from equity offering, net of underwriting discounts   179,306        
Repurchase of outstanding equity / Portillo’s OpCo units   (179,306 )      
Distributions paid to non-controlling interest holders   (399 )      
Proceeds from stock option exercises   1,015       1,451  
Employee withholding taxes related to net settled equity awards   (56 )      
Proceeds from Employee Stock Purchase Plan purchases   297        
Payments of Tax Receivable Agreement liability   (813 )      
Payment of deferred financing costs   (3,569 )      
Payment of initial public offering issuance costs         (771 )
NET CASH USED IN FINANCING ACTIVITIES   (15,953 )     (982 )
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH   (21,970 )     10,467  
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD   44,427       39,263  
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD $ 22,457     $ 49,730  
       

PORTILLO’S INC

SELECTED OPERATING DATA AND NON-GAAP FINANCIAL MEASURES
       
  Quarter Ended   Two Quarters Ended
  June 25, 2023   June 26, 2022   June 25, 2023   June 26, 2022
Total Restaurants (a)   76       71       76       71  
AUV (in millions) (a) N/A   N/A   $ 8.8     $ 8.3  
Change in same-restaurant sales (b)   5.9 %     1.9 %     7.4 %     4.8 %
Adjusted EBITDA (in thousands) (b) $ 29,223     $ 27,613     $ 48,856     $ 45,244  
Adjusted EBITDA Margin (b)   17.3 %     18.3 %     15.0 %     15.9 %
Restaurant-Level Adjusted EBITDA (in thousands) (b) $ 42,731     $ 38,386     $ 77,550     $ 66,369  
Restaurant-Level Adjusted EBITDA Margin (b)   25.3 %     25.5 %     23.8 %     23.3 %

(a) Includes a restaurant that is owned by C&O of which Portillo’s owns 50% of the equity. AUVs for the quarters ended June 25, 2023 and June 26, 2022 represent AUVs for the twelve months ended June 25, 2023 and June 26, 2022, respectively. Total restaurants indicated are as of a point in time.
(b) Excludes a restaurant that is owned by C&O of which Portillo’s owns 50% of the equity.

PORTILLO’S INC.

NON-GAAP FINANCIAL MEASURES

To supplement the consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: Adjusted EBITDA and Adjusted EBITDA Margin, and Restaurant-Level Adjusted EBITDA and Restaurant-Level Adjusted EBITDA Margin. Accordingly, these measures are not required by, nor presented in accordance with GAAP, but rather are supplemental measures of operating performance of our restaurants. You should be aware that these measures are not indicative of overall results for the Company and that Restaurant-Level Adjusted EBITDA and Restaurant-Level Adjusted EBITDA Margin do not accrue directly to the benefit of stockholders because of corporate-level expenses excluded from such measures. These measures are supplemental measures of operating performance and our calculations thereof may not be comparable to similar measures reported by other companies. These measures are important measures to evaluate the performance and profitability of our restaurants, individually and in the aggregate, but also have important limitations as analytical tools and should not be considered in isolation as substitutes for analysis of our results as reported under GAAP.

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA represents net income before depreciation and amortization, interest expense and income taxes, adjusted for the impact of certain non-cash and other items that we do not consider in our evaluation of ongoing core operating performance as identified in the reconciliation of net income (loss), the most directly comparable GAAP measure to Adjusted EBITDA. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of total revenues.

We use Adjusted EBITDA and Adjusted EBITDA Margin (i) to evaluate our operating results and the effectiveness of our business strategies, (ii) internally as benchmarks to compare our performance to that of our competitors and (iii) as factors in evaluating management’s performance when determining incentive compensation.

We believe that Adjusted EBITDA and Adjusted EBITDA Margin are important measures of operating performance because they eliminate the impact of expenses that do not relate to our core operating performance.

Restaurant-Level Adjusted EBITDA and Restaurant-Level Adjusted EBITDA Margin

Restaurant-Level Adjusted EBITDA is defined as revenue, less restaurant operating expenses, which include food, beverage and packaging costs, labor expenses, occupancy expenses and other operating expenses. Restaurant-Level Adjusted EBITDA excludes corporate level expenses and depreciation and amortization on restaurant property and equipment. Restaurant-Level Adjusted EBITDA Margin represents Restaurant-Level Adjusted EBITDA as a percentage of revenue.

We believe that Restaurant-Level Adjusted EBITDA and Restaurant-Level Adjusted EBITDA Margin are important measures to evaluate the performance and profitability of our restaurants, individually and in the aggregate.

See below for a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted EBITDA and Adjusted EBITDA Margin (in thousands):

  Quarter Ended   Two Quarters Ended
  June 25, 2023   June 26, 2022   June 25, 2023   June 26, 2022
Net income $ 9,898     $ 10,756     $ 8,625     $ 11,306  
Depreciation and amortization   5,941       5,309       11,610       10,514  
Interest expense   6,523       6,097       13,966       12,196  
Loss on debt extinguishment               3,465        
Income tax expense   1,542       2,340       983       2,505  
EBITDA   23,904       24,502       38,649       36,521  
Deferred rent (1)   1,169       865       2,393       1,946  
Equity-based compensation   4,184       3,864       7,720       7,649  
Other loss (2)   377       93       496       125  
Transaction-related fees & expenses (3)   168       43       761       757  
Tax Receivable Agreement liability adjustment (4)   (579 )     (1,754 )     (1,163 )     (1,754 )
Adjusted EBITDA $ 29,223     $ 27,613     $ 48,856     $ 45,244  
Adjusted EBITDA Margin (5)   17.3 %     18.3 %     15.0 %     15.9 %

(1) Represents the difference between cash rent payments and the recognition of straight-line rent expense recognized over the lease term.
(2) Represents loss on disposal of property and equipment.
(3) Represents the exclusion of certain expenses that management believes are not indicative of ongoing operations, consisting primarily of certain professional fees.
(4) Represents remeasurement of the Tax Receivable Agreement liability.
(5) Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenues, net.

See below for a reconciliation of operating income, the most directly comparable GAAP measure, to Restaurant-Level Adjusted EBITDA and Restaurant-Level Adjusted EBITDA Margin (in thousands):

  Quarter Ended   Two Quarters Ended
  June 25, 2023   June 26, 2022   June 25, 2023   June 26, 2022
Operating income $ 17,384     $ 17,439     $ 25,876     $ 24,253  
Plus:              
General and administrative expenses   19,609       15,439       38,387       31,126  
Pre-opening expenses   275       423       2,619       979  
Depreciation and amortization   5,941       5,309       11,610       10,514  
Net income attributable to equity method investment   (381 )     (275 )     (588 )     (398 )
Other (income) loss, net   (97 )     51       (354 )     (105 )
Restaurant-Level Adjusted EBITDA $ 42,731     $ 38,386     $ 77,550     $ 66,369  
Restaurant-Level Adjusted EBITDA Margin (1)   25.3 %     25.5 %     23.8 %     23.3 %

(1) Restaurant-Level Adjusted EBITDA Margin is defined as Restaurant-Level Adjusted EBITDA divided by Revenues, net



Oatly and Amazon Expand Relationship to Meet Growing Demand for Plant-Based Drinks Across Europe

Companies expand on successful relationship in the UK where Oatly is already a top 30 grocery product for Amazon

MALMÖ, Sweden, Aug. 03, 2023 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY)(“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced an expansion of its direct relationship with Amazon through a new pan-European arrangement that will see a range of Oatly’s Oat Drink products made available on Amazon beginning later this year across key European markets – including Germany, France, Italy, Spain, Netherlands and Belgium.

Under the arrangement, Oatly will have the ability to list several of its popular Oat Drink lines across the markets including Oatly Barista Edition, Oatly Light, Oatly Semi, Oatly Whole, Oatly “No” Sugars and Mini Barista. Amazon Prime members will be able to access Oatly products with next day and subscribe and save delivery options.

Since launching a direct relationship with Amazon in the UK in October of last year, Oatly Barista Edition has regularly performed in the top 30 of all grocery products and is currently #1 in oat drink sales on Amazon in the UK. Oatly has formed a new pan-European business group to manage the Amazon relationship, which will be led by its General Manager of UK & Ireland, Bryan Carroll.

“We’re excited to build on the successful relationship we’ve had with Amazon in the UK and look forward to making more Oatly products available to more Amazon customers across Europe,” said Daniel Ordoñez, Chief Operating Officer at Oatly. “Amazon is an important part of our customer mix that helps support our mission to make plant-based drinks increasingly accessible and affordable to people and small businesses everywhere for the benefit of our planet.”

Oatly plans to produce a fully enclosed bespoke packaging solution for Amazon customers, allowing shipment straight through Amazon’s supply chain. This removes the need for additional packaging and further reduces the carbon footprint of purchasing via this channel compared to customary packaging.

Scaling of the relationship follows recent reports that sales of plant-based milks have increased by 20% across Europe1. The Good Food Institute Europe reported sales of plant-based foods were on the rise, amounting to €5.7 billion in 2022, with plant-based milks leading the category.

1
GFI EUROPE / Europe: Plant-Based Foods Retail Market Report (2020-2022)

About Oatly

We are the world’s original and largest oat drink company. For over 25 years, we have exclusively focused on developing expertise around oats: a global power crop with inherent properties suited for sustainability and human health. Our commitment to oats has resulted in core technical advancements that enabled us to unlock the breadth of the dairy portfolio, including alternatives to milks, ice cream, yogurt, cooking creams, spreads and on-the-go drinks. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 20 countries globally.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, regarding the business and expanded relationship with Amazon, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate,” “will,” “aim,” “potential,” “continue,” “is/are likely to” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: general economic conditions including high inflationary cost pressures; our history of losses and inability to achieve or sustain profitability; the impact of the COVID-19 pandemic, including the spread of variants of the virus, on our business and the international economy; any failure to obtain necessary capital when needed on acceptable terms; a cybersecurity incident or other technology disruptions; changing consumer preferences and our ability to adapt to new or changing preferences; and the other important factors discussed under the caption “Risk Factors” in Oatly’s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on April 19, 2023 and other filings with the SEC as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Oatly disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law. 



Contacts

Oatly Group AB
+1 866-704-0391
[email protected]
[email protected]

Freshworks Unveils AI-Powered Customer Service Suite with Freddy Generative AI Integration

SAN MATEO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Freshworks Inc., (NASDAQ: FRSH) today announced the launch of its AI-powered Customer Service Suite which brings together self-service bots, agent-led conversational messaging, and automated ticketing management in an all-in-one solution. Uniting Freshchat™, Freshdesk™, and the company’s generative artificial intelligence technology, Freddy AI, the Freshworks Customer Service Suite enables a modern customer support experience accessible to any company, with pricing that scales from small business to global enterprise.

Ninety four percent of business leaders surveyed in Deloitte’s State of AI in the Enterprise, 5th Edition, agree that AI is critical to success over the next five years. However, many (42%) see implementing AI technologies a barrier to doing that. Freshworks Customer Service Suite
is easy-to-implement, easy-to-use, and easy-to-scale solution for companies looking to leverage AI to retain and delight their customers.

“At Freshworks, we’ve always been committed to delivering innovative solutions that anticipate the needs of our customers. The new Freshworks Customer Service Suite is firmly rooted in generative AI technology and empowers businesses to automate customer resolutions, supercharge agent productivity and make smart decisions quickly at a price point that every company wants,” said Freshworks’ Chief Product Officer Prakash Ramamurthy.

The Freshworks Customer Service Suite follows the June beta launch of Freddy Self Service, Copilot, and Insights, which brought generative AI enhancements to a wide range of Freshworks products, and builds upon Freshworks’ generative AI enhancements released in March, which are already reducing agent time required on certain tasks by more than 80%.

Using Freshworks’ Freddy AI capabilities with the Customer Service Suite, companies of all sizes can:

  • Automate and personalized self-service across channels. Freddy Self Service AI-powered bots work across channels to help customers find answers fast. Ticket deflection happens faster and customers receive an overall better experience with personalized resolutions.
  • Supercharge agent productivity and collaboration. Freddy Copilot equips agents with next-best-action suggestions, streamlines workflows and enables them to deliver accurate and personalized service. Integration with an advanced ticketing system promotes seamless teamwork among departments.
  • Leverage actionable Insights to make smarter decisions. Freddy Insights continuously analyzes data to surface key issues, make recommendations to fix those issues, and generate reports using conversational prompts.

The all-in-one Suite offers value for businesses seeking to elevate their customer support capabilities with more engaging customer experiences and improved agent productivity.

Freshdesk customer, David Yabubik, Director of Customer Support atRestaurant365, said, “We have big aspirations for the future and if we are ever going to hit the kind of revenue, service margins, and scale of support, we’re going to need to get more efficient and automate our work. AI promises to do just that, with a potential game changer in the Freshworks Customer Service Suite.”

Frank Servidio, Director of Service Operations at Ryan Specialty, said, “Our existing Freshdesk knowledge base automations combined with the new Freddy AI Self-Service capabilities will play very nicely with the Freshchat bots we are implementing. We’re expecting bots and automations will decrease tickets by at least 10 percent, probably more.”

Read more about the Customer Service Suite on our blog: https://www.freshworks.com/customer-service-generative-ai-blog/
Experience a free trial by signing up on our website: https://www.freshworks.com/customer-service-suite/demo-request/

About Freshworks

Freshworks Inc., (NASDAQ: FRSH) creates business software anyone can use. Purpose-built for IT, customer support, and sales and marketing teams, our AI-boosted products are designed to let everyone work more efficiently and deliver more value for immediate business impact. Headquartered in San Mateo, California, Freshworks operates around the world to serve more than 65,000 customers, including American Express, Blue Nile, Bridgestone, Databricks, Fila, Klarna, and OfficeMax. For the freshest company news, visit www.freshworks.com and follow us on Facebook, LinkedIn, and Twitter.

© 2023 Freshworks Inc. All Rights Reserved. Freshworks and its associated logo is a trademark of Freshworks Inc. All other company, brand and product names may be trademarks or registered trademarks of their respective companies. Nothing in this press release should be construed to the contrary, or as an approval, endorsement or sponsorship by any third party of Freshworks Inc. or any aspect of this press release.

Media Relations Contact:

Erika Howard
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d49f6fcc-bf23-4b33-8f03-d324b0508cfa.



Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023

Management to host conference call and webcast at 5:30pm EDT

EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2023 after the markets close on Thursday, August 10, 2023. The company will host a corporate update conference call and live audio webcast at 5:30 p.m. on that day.

 
Live Conference Call & Webcast:
Toll Free:  877-407-3982
International:   201-493-6780
Conference ID:  13739784
Call me™: Link here
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1623390&tp_key=3efc160cb8
   

A replay of the webcast will be available in the Investors section of the Predictive Oncology website at https://investors.predictive-oncology.com/events-and-presentations.

About Predictive Oncology

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the Company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Eagan, MN.    

Contact:

Predictive Oncology Inc.
Theresa Ferguson, Senior Director of Marketing
Phone: (630) 566-2003
[email protected]

Predictive Oncology Investor Relations
Tim McCarthy  
LifeSci Advisors, LLC.  
[email protected]  

Forward-Looking Statements:

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

 



Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

— NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022

–Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), (“Paratek” or “the Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the second quarter ended June 30, 2023.


Recent Highlights

  • BARDA Contract Modification: The Company executed a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Administration for Strategic Preparedness and Response (“ASPR”) within the U.S. Department of Health and Human Services, in July 2023.

    • BARDA and Paratek have agreed the next procurement of NUZYRA anthrax treatment courses will be split into two equal procurements based on the achievement of specific development milestones toward both treatment and post-exposure prophylaxis (“PEP”) indications of pulmonary anthrax.
      • The first of these procurements will be triggered by the delivery of positive top-line data from a dose-ranging efficacy study for PEP of inhalation anthrax in non-human primates (“NHPs”). The company expects this data to be available in the first quarter of 2024.
      • The second of these procurements will be triggered by BARDA’s receipt of positive top-line data from a combination of two studies, a dose-ranging efficacy study in NHPs and a pivotal efficacy study in rabbits for the treatment of inhalation anthrax, which the company anticipates could be available as early as the fourth quarter of 2024. 
  • Non-Tuberculous Mycobacteria (“NTM”) Rare Disease Program: The Company announced that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products (“COMP”) recommended a positive opinion for orphan medicinal product designation for NUZYRA for the treatment of NTM lung disease in June 2023. The European Commission officially designated NUZYRA as an orphan medicinal product in July 2023.


Second Quarter 2023 Financial Results

Total revenue for the second quarter of 2023 was $40.0 million compared to $29.6 million for the same period in the prior year. Total revenue for the second quarter of 2023 was comprised of the following:

  • NUZYRA net U.S. sales of $33.8 million, which represented a 35% increase from $25.1 million for the same period in the prior year.
  • Government contract service and grant revenue earned from cost reimbursement under the BARDA contract of $5.6 million, a 40% increase from $4.0 million for the same period in the prior year.
  • Collaboration and royalty revenue of $0.6 million, consistent with $0.6 million for the same period in the prior year, both of which primarily represent royalty revenues earned on sales of NUZYRA in China and on sales of SEYSARA® (sarecycline) in the United States.

Research and development (“R&D”) expenses were $8.8 million for the second quarter of 2023, compared to $7.6 million for the same period in the prior year.

Selling, general and administrative (“SG&A”) expenses were $36.3 million for the second quarter of 2023, compared to $30.3 million for the same period in the year. The increase in SG&A expenses is primarily the result of costs incurred in connection with the potential acquisition of Paratek by Gurnet Point and Novo Holdings.

Paratek reported a net loss of $14.6 million, or $(0.25) per share, for the second quarter of 2023, compared to a net loss of $17.7 million, or $(0.33) per share, for the same period in the prior year.

Paratek had cash and cash equivalents of $42.7 million as of June 30, 2023. Based upon the Company’s current operating plan, if it is unable to consummate the merger with Gurnet Point and Novo Holdings, as described below, there is substantial doubt about the Company’s ability to operate as a going concern.


Proposed Gurnet Point Capital and Novo Holdings A/S Transaction

On June 6, 2023, Paratek announced it entered into a definitive agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) in a transaction valued at approximately $462 million, including the assumption of debt and assuming full payment of a Contingent Value Right (“CVR”). Debt financing of $175 million for this transaction will be provided by funds managed by Oaktree Capital Management, L.P.

Under the terms of the merger agreement, Gurnet Point, a leading healthcare investment firm, and Novo Holdings, a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire all outstanding shares of Paratek for $2.15 per share in cash at close, plus a CVR of $0.85 per share payable upon the achievement of $320 million in U.S. NUZYRA net sales (excluding certain permitted deductions, payments under Paratek’s contract with ASPR-BARDA, certain government payments and certain royalty revenue) in any calendar year ending on or prior to December 31, 2026.

The transaction, which the Paratek Board of Directors has unanimously approved, is expected to close in the third quarter of 2023, subject to customary closing conditions, including approval by Paratek shareholders and receipt of regulatory approvals. Following completion, Paratek will become a private company and will no longer be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, nor be traded on Nasdaq Global Market.

Due to the pending transaction, Paratek will not host a conference call to discuss its quarterly financial results or comment on its financial guidance for the year ending December 31, 2023.


About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax.

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.


About NUZYRA
®

NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals and other drug-resistant strains. 


Forward Looking Statements

This press release contains forward-looking statements including statements related to the expected timing of closing of our sale to Gurnet Point and Novo Holdings, our overall strategy, products, prospects, potential and expected results, including statements about our expectations regarding the Company’s future growth and performance, revenue and operating expense projections, our ability to continue to execute and deliver on our BARDA contract, the status of our NTM development program, and our ability to operate as a going concern.

All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as “expect,” “anticipate,” “continue,” “will” and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

PARATEK PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands)

      As of June 30,        December 31,  
      2023       2022  
Cash, cash equivalents and marketable securities   $ 42,685     $ 34,248  
Total assets     145,792       172,538  
Working capital     (97,392 )     99,454  
Total current liabilities     202,619       37,388  
Long-term debt     94,285       256,946  
Common stock and additional paid-in capital     763,780       759,407  
Accumulated deficit     (965,145 )     (930,449 )
Total stockholders’ deficit     (201,365 )     (171,042 )

Condensed Consolidated Statement of Operations

(unaudited)

(in thousands, except loss per share data)



  Three Months Ended
June 30,
Six Months Ended
June 30,
    2023     2022     2023     2022  
Product revenue, net $ 33,800   $ 25,082   $ 60,013   $ 45,000  
Government contract service revenue   3,620     1,896     5,301     4,068  
Government contract grant revenue   1,931     2,082     4,084     4,182  
Collaboration and royalty revenue   642     577     1,831     1,248  
Net revenue $ 39,993   $ 29,637   $ 71,229   $ 54,498  
Expenses:        
Cost of product revenue   4,368     4,878     10,612     8,372  
Research and development   8,772     7,592     16,080     15,069  
Selling, general and administrative   36,264     30,335     69,753     57,937  
Total operating expenses   49,404     42,805     96,445     81,378  
Loss from operations   (9,411 )   (13,168 )   (25,216 )   (26,880 )
Other income and expenses:        
Interest income   252     133     473     240  
Interest expense   (5,287 )   (4,546 )   (9,763 )   (9,025 )
Other (losses) gains, net   (56 )   (38 )   (78 )   138  
Net loss before provision for income taxes $ (14,502 ) $ (17,619 ) $ (34,584 ) $ (35,527 )
Provision for income taxes   (51 )       (111 )    
Net loss   (14,553 )   (17,619 )   (34,695 )   (35,527 )
Other comprehensive (loss)        
Unrealized (loss) on available-for-sale securities, net of tax       (53 )       (224 )
Comprehensive loss $ (14,553 ) $ (17,672 ) $ (34,695 ) $ (35,751 )
Basic and diluted net loss per common share $ (0.25 ) $ (0.33 ) $ (0.61 ) $ (0.67 )
Weighted average common stock outstanding        
Basic   57,282,239     53,023,350     57,093,876     53,310,091  
Diluted   57,282,239     53,023,350     57,093,876     53,310,091  
         

CONTACT:

Investor Relations:
PJ Kelleher
LifeSci Advisors
[email protected]
Phone: 617-430-7579

Media:
Christine Fanelle
Scient PR
[email protected]
Phone: 215-595-5211



Eyenovia Announces First Commercial Sale of Mydcombi™

Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation

Validates Eyenovia’s proprietary Optejet
®
dispensing platform

World-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe becomes first to incorporate Mydcombi into his daily practice

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced the first commercial sale of Mydcombi. Mydcombi was approved by the US Food and Drug Administration on May 8, 2023. The initial sale was to world-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe, who has become the first physician in the U.S. to incorporate Mydcombi into his daily practice.

“We are very pleased to initiate sales of Mydcombi to select professional offices so that ophthalmologists, optometrists, technicians and their patients can experience the benefits of Mydcombi’s metered spray delivery relative to conventional multiple eye drops,” stated Michael Rowe, chief executive officer of Eyenovia. “We have now kicked off our targeted launch while we continue to ramp up our internal manufacturing capabilities.”

“I have been eagerly awaiting the commercial availability of Mydcombi to provide a great experience to my patients who require pupil dilation,” stated Dr. Radcliffe. “In addition, given the potential for streamlining patient throughput that Mydcombi may facilitate, I anticipate that it will be the go-to mydriasis agent in my own practice going forward.”

Mydcombi is designed to streamline the estimated 106 million office-based comprehensive eye exams with pupil dilation performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for ocular surgery. In clinical studies, Mydcombi was statistically superior to tropicamide and to phenylephrine administered alone, with effective pupil dilation in almost two thirds of patients seen as early as 20 minutes after application, with excellent tolerability. The product should not be used in patients with known hypersensitivity to any component of the formulation.

IMPORTANT SAFETY INFORMATION for MYDCOMBI



 (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

INDICATIONS

MYDCOMBI is indicated to induce mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired

CONTRAINDICATIONS: In patients with known hypersensitivity to any component of the formulation

WARNINGS AND PRECAUTIONS

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION
This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reaction and behavioral disturbance due to hypersensitivity to anticholinergic drugs should be considered.
Mydriatics may produce a transient elevation of intraocular pressure.
Significant elevations in blood pressure have been reported. Caution in patients with elevated blood pressure.
Rebound miosis has been reported one day after installation.
Remove contact lenses before using.

DRUG INTERACTIONS

Atropine-like Drugs: May exaggerate the adrenergic pressor response
Cholinergic Agonists and Ophthalmic Cholinesterase Inhibitors: May interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors
Potent Inhalation Anesthetic Agents: May potentiate cardiovascular depressant effects of some inhalation anesthetic agents

ADVERSE REACTIONS

  • Most common ocular adverse reactions include transient blurred vision, reduced visual acuity, photophobia, superficial punctate keratitis, and mild eye discomfort. Increased intraocular pressure has been reported following the use of mydriatics.
  • Systemic adverse reactions including dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide.

To report SUSPECTED ADVERSE REACTIONS, contact Eyenovia, Inc. At 1-833-393-6684 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch)

Please go to www.mydcombi.com for FULL PRESCRIBING INFORMATION

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the commercialization of Mydcombi for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking Statements

Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:

Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]

Eyenovia Investor Contact:

Eric Ribner
LifeSci Advisors, LLC
[email protected]
(646) 751-4363

Eyenovia Media Contact:

Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
[email protected]